BioSpace News Archive

StageZero Life Sciences Ltd. announces that it is restating its financial statements for the three and nine months ended September 30, 2020, along with a corresponding restated management discussion and analysis.

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol outperforms the other listing drugs for the treatment of relapsed AML patients in its Phase 2 clinical study conducted in Russia.

Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.

Agreement Aims to Help UK Meet its Goal of Diagnosing Three-Quarters of All Cancers at an Early Stage by 2028

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced their third quarter 2020 financial results.

Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited.

Crescita Therapeutics Inc. announced that the Toronto Stock Exchange has approved the Company’s intention to make a normal course issuer bid for a portion of its common shares as appropriate opportunities arise from time to time.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

The global fertility testing devices market is expanding at a significant rate owing to increase in awareness toward fertility testing, worldwide.

Growing incidence of chronic and infectious diseases is anticipated to fuel demand for immunoassay.